For cases of advanced skin cancer that are not candidates for surgery or radiation therapy, we have Hedgehog pathway inhibitors and PD-1 inhibitors, each of which has 2 approved medications, noted Todd Schlesinger, MD, FAAD.
For cases of advanced skin cancer that are not candidates for surgery or radiation therapy, we have Hedgehog pathway inhibitors and PD-1 inhibitors, each of which has 2 approved medications, noted Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.
Schlesinger presented “Managing Advanced Non-Melanoma Skin Cancer - Choosing the Right Pathway for the Right Patient,” at this year’s American Academy of Dermatology Virtual Meeting Experience.
Transcript
What drug classes are used to treat advanced skin cancers?
So by advanced skin cancer, we’re talking about skin cancers that are not necessarily candidates for surgery or radiation therapy. Also, skin cancers that may be locally advanced and/or metastatic. The metastatic rate for squamous cell carcinoma hovers between 3% and 5%, and the metastatic rate for basal cell carcinoma is well less than 1%. But many tumors that we see in our practice may have been treated with other modalities if they are advanced, such as chemotherapy, radiation therapy, or prior surgery.
We have 2 major classes of medical therapies now that we can use for these advanced cases. One class is the Hedgehog pathway inhibitor class, of which we have 2 approved medications, and the other class is the PD-1 inhibitor pathway, of which we also have 2 approved medications. These are the kinds of medicines that would be used.
For the Hedgehog inhibitors, we have vismodegib and sonidegib. Both these medications have their pluses and minuses and are typically used for the medium to long term for patients with advanced basal cell carcinoma. And then for both squamous cell carcinoma and basal cell carcinoma, the PD-L1 pathway, or the checkpoint inhibitor pathway, is also used. These drugs are given by IV [intravenous] infusion as opposed to the Hedgehog pathway inhibitors, which are given orally.
The IV infusion medications, like the Hedgehog pathway [inhibitors], have their own set of adverse events that we have to watch for. For both medications, adverse events can occur, will occur frequently, in many to most patients, and the key to managing the adverse events is to recognize them early and intervene early with the medications.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More